Isolation of Mesenchymal Stem Cells from Amniotic Fluid and Placenta

Steigman, Shaun A.; Fauza, Dario O.

doi:10.1002/9780470151808.sc01e02s35

Cited by 3 publications

(2 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The collection of amniotic fluid during routine cesarean deliveries is also a promising method [105]. A method of extracting MSCs from the placenta was introduced by Steigman and Fauza [106], who indicated that by chorionic villus sampling or blunt dissection, the fetal placental specimen could be mechanically separated from the maternal decidua [107]. Currently, almost all studies of AF-MSCs and placenta-derived MSCs (PMSCs) in renal fibrosis are in animal models.…”

Section: Mechanisms and Functions Of Mscs In Renal Fibrosis Therapymentioning

confidence: 99%

Mesenchymal Stem Cells in Renal Fibrosis: The Flame of Cytotherapy

Zhuang

Yin

et al. 2019

Stem Cells International

View full text Add to dashboard Cite

Renal fibrosis, as the fundamental pathological process of chronic kidney disease (CKD), is a pathologic extension of the normal wound healing process characterized by endothelium injury, myofibroblast activation, macrophage migration, inflammatory signaling stimulation, matrix deposition, and remodelling. Yet, the current method of treating renal fibrosis is fairly limited, including angiotensin-converting enzyme inhibition, angiotensin receptor blockade, optimal blood pressure control, and sodium bicarbonate for metabolic acidosis. MSCs are pluripotent adult stem cells that can differentiate into various types of tissue lineages, such as the cartilage (chondrocytes), bone (osteoblasts), fat (adipocytes), and muscle (myocytes). Because of their many advantages like ubiquitous sources, convenient procurement and collection, low immunogenicity, and low adverse effects, with their special identification markers, mesenchymal stem MSC-based therapy is getting more and more attention. Based on the mechanism of renal fibrosis, MSCs mostly participate throughout the renal fibrotic process. According to the latest and overall literature reviews, we aim to elucidate the antifibrotic mechanisms and effects of diverse sources of MSCs on renal fibrosis, assess their efficacy and safety in preliminarily clinical application, answer the controversial questions, and provide novel ideas into the MSC cellular therapy of renal fibrosis.

show abstract

Section: Mechanisms and Functions Of Mscs In Renal Fibrosis Therapymentioning

confidence: 99%

Mesenchymal Stem Cells in Renal Fibrosis: The Flame of Cytotherapy

Zhuang

Yin

et al. 2019

Stem Cells International

View full text Add to dashboard Cite

show abstract

“…Others isolation techniques are a single-stage method (for adhering AF cells) (Graham and Fauza 2007) and two-stage method (Tsai et al 2004) (for nonadhering AF cells). Both of them after obtaining written consent, AF was centrifuged, the cell pellets are seeded in special cell culture media such as DMEM (high glucose DMEM) (Steigman and Fauza 2007) or M199 (In 't Anker et al 2004, Bossolasco et al 2006b) or Iscove's modified Dulbecco's medium (IMDM) (Cipriani et al 2007) or alpha MEM with 20% of Chang medium (Chang B plus Chang C) this procedure for single-stage method was continued for 2-3 weeks and twice per week cells medium was changed (Chiavegato et al 2007).…”

Section: How To Isolate and Characterize Afscs?mentioning

confidence: 99%

An update clinical application of amniotic fluid-derived stem cells (AFSCs) in cancer cell therapy and tissue engineering

Aziz

Fathi

Rahmati-Yamchi

et al. 2016

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

Recent studies have elucidated that cell-based therapies are promising for cancer treatments. The human amniotic fluid stem (AFS) cells are advantageous cells for such therapeutic schemes that can be innately changed to express therapeutic proteins. HAFSCs display a natural tropism to cancer cells in vivo. They can be useful in cancer cells targeting. Moreover, they are easily available from surplus diagnostic samples during pregnancy and less ethical and legal concern are associated with the collection and application than other putative cells are subjected. This review will designate representatives of amniotic fluid and stem cell derived from amniotic fluid. For this propose, we collect state of human AFS cells data applicable in cancer therapy by dividing this approach into two main classes (nonengineered and engineered based approaches). Our study shows the advantage of AFS cells over other putative cells types in terms differentiation ability to a wide range of cells by potential and effective use in preclinical studies for a variety of diseases. This study has shown the elasticity of human AFS cells and their favorable potential as a multipotent cell source for regenerative stem cell therapy and capable of giving rise to multiple lineages including such as osteoblasts and adipocyte.

show abstract

Stem cell sources from human biological waste material: a role for the umbilical cord and dental pulp stem cells for regenerative medicine

Das

Sloan

2023

Human Cell

View full text Add to dashboard Cite

Isolation of Mesenchymal Stem Cells from Amniotic Fluid and Placenta

Cited by 3 publications

References 48 publications

Mesenchymal Stem Cells in Renal Fibrosis: The Flame of Cytotherapy

Mesenchymal Stem Cells in Renal Fibrosis: The Flame of Cytotherapy

An update clinical application of amniotic fluid-derived stem cells (AFSCs) in cancer cell therapy and tissue engineering

Stem cell sources from human biological waste material: a role for the umbilical cord and dental pulp stem cells for regenerative medicine

Contact Info

Product

Resources

About